Carbonell Estrany X, Quero Jiménez J
Hospital Clínic-Maternitat,Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Unitat Integrada de Pediatria, Universitat de Barcelona.
An Esp Pediatr. 2000 Apr;52(4):372-4.
Premature babies < = 35 weeks gestation, with or without chronic lung disease (CLD), should be considered high risk population for RSV infection and rehospitalization. RSV monoclonal antibodies (palivizumab) have been found useful in decreasing rates of RSV hospitalization in this patients. Guidelines for their administration include: 1. Recommend their use in premature born between 29-32 weeks gestation without CLD and less than 6 months at entry of RSV station. 2. Strongly recommend their use in premature babies < = 28 weeks gestation or affected with CLD in treatment during last 6 months. These patients should be prophylaxed for two RSV seasons. 3. Prophylaxis among premature babies between 32-35 weeks gestation is not recommended on routine bases. Each case has to be individually analyzed considering risk factors.
孕周≤35周的早产儿，无论有无慢性肺部疾病（CLD），均应被视为呼吸道合胞病毒（RSV）感染和再次住院的高危人群。已发现RSV单克隆抗体（帕利珠单抗）有助于降低该类患者的RSV住院率。其给药指南包括：1. 建议在孕周29 - 32周、无CLD且进入RSV流行季时年龄小于6个月的早产儿中使用。2. 强烈建议在孕周≤28周或在过去6个月内患有CLD的早产儿治疗期间使用。这些患者应接受两个RSV流行季的预防。3. 不常规推荐对孕周32 - 35周的早产儿进行预防。必须根据风险因素对每个病例进行单独分析。
